Concepedia

Jennifer I. Hare

JI

Statistics

Publications

7

Citations

234

H-Index

7

Active since

2010

Affiliations

AstraZeneca (United Kingdom)(Current)

University of Alberta

University of Nottingham

BC Cancer Agency

Centre for Drug Research and Development

Jennifer I. Hare is an author at AstraZeneca (United Kingdom) specializing in medicine, nanomedicine, and radiation oncology.

Top concepts

Publications per year

2010–2017

7

Publications

7

Development of a liposomal nanoparticle formulation of 5-Fluorouracil for parenteral administration: Formulation design, pharmacokinetics and efficacy

A.M. Thomas, Anita I. Kapanen, Jennifer I. Hare et al. · Journal of Controlled Release · 2010 · 75 citations

, , +11

Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers

R. England, Jennifer I. Hare, Jennifer Barnes et al. · Journal of Controlled Release · 2016 · 47 citations · Full text

, , +9

Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil

Jennifer I. Hare, Robert W. Neijzen, Malathi Anantha et al. · PLoS ONE · 2013 · 32 citations · Full text

Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer

Jennifer I. Hare, Elaine H. Moase, Theresa M. Allen · Journal of drug targeting · 2012 · 25 citations

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?

Ross A. Little, Hervé Barjat, Jennifer I. Hare et al. · Magnetic Resonance Imaging · 2017 · 22 citations · Full text

1–5 of 7